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Hepatobilliary surgerySummary Solid tumours in the tail of the pancreas may present a diagnostic dilemma if the clinical
history, imaging features or cytology is not conclusive. The common differential diagnoses for a
pancreatic tail mass are a primary malignancy, neuroendocrine tumour or a retroperitoneal tumour.
However a comparison to the adjacent spleen on imaging may help identify aberrant splenic tissue.
We present the case of an incidental finding of a solid tumour in the tail of the pancreas, which was
resected and a histological diagnosis of an intrapancreatic spleen (IPAS) was made. A suspicion of
IPAS when reviewing the imaging may have prevented the resection of a benign tumour.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Case report
A 65 year old Caucasian male presented with severe
abdominal and back pain. His past medical history includes
diet controlled diabetes and hypertension. A ruptured
abdominal aneurysm was suspected and the patient under-
went an arterial phase contrast CT angiogram. This showed
an aneurysmal abdominal aorta (3.8 cm) and a lesion in the
tail of the pancreas measuring 47 by 29 mm (Fig. 1). The
lesion appeared denser than the surrounding pancreas, and
the differential diagnosis included a pancreatic primary
malignant lesion or a retroperitoneal sarcoma. A low
attenuating lesion in the liver was also identified which
was difficult to characterise due to its size (9.5 mm). The
patient's abdominal pain settled with conservative manage-
ment, however he had persistent back pain. Subsequent
endoscopic ultrasounds and biopsies of the pancreatic lesion⁎ Corresponding author.
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censes/by-nc-nd/3.0/).were inconclusive (unspecific inflammatory cells only). The
patient underwent a repeat CT six months later, which
showed that therewas no change in the characteristics or size
of the pancreatic lesion. Due to the indeterminate nature of
the mass and persistent back pain, the patient elected to have
a surgical resection. He underwent a laparoscopic distal
pancreatectomy and splenectomy with no postoperative
complications. He made an uneventful recovery, although
the back pain still persisted.2. Histology and immunohistochemistry
Histological examination of the specimen showed a well-
defined encapsulated mass within the tail of the pancreas.
The morphological features of the mass were identical to
splenic tissue. Although mostly separated from pancreatic
tissue by a thick fibrous capsule (Fig. 2A), several sections
showed merging of the surrounding pancreatic tissue with
the capsule as well as the accessory splenic tissue.ess article under the CC BY-NC-ND license (http://creativecommons.org/
Fig. 1 CT abdomen showing a dense mass in the tail of the
pancreas, with similar attenuation as the spleen.
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pancreatic and splenic tissue, with pancreatic tissue staining
negatively with LCA and splenic tissue highlighted by LCA
(Fig. 2B). The histological findings were consistent with a
diagnosis of an intrapancreatic accessory spleen.3. Discussion
3.1. Embryology
An accessory spleen derives from embryological aberra-
tion during splenic development, when a focus of splenic
tissue arises separate from the main body of the spleen.
Majority of accessory spleens are found around the splenic
hilum and are not of clinical significance. They occur in up toFig. 2 A, Sections from the distal pancreatectomy show the p
completely surrounded by pancreatic tissue. The morphological featu
stained section. B, Immunohistochemistry confirms the merging of th
by LCA and the surrounding pancreatic tissue is negative. IHC for L30% of the population [1] and majority are found around the
splenic hilum. An intrapancreatic spleen (IPAS), although the
second commonest location for an accessory splenunculus, is
still an uncommon finding [2]. Its clinical significance is in its
misdiagnosis and subsequent unnecessary surgical
intervention.3.2. Diagnosis
IPAS is rarely symptomatic, and diagnosis is difficult if
it is not suspected or misdiagnosed [3]. Several imaging
modalities, used to visualise pancreatic lesions may aid a
diagnosis of IPAS.
3.3. Ultrasound
On ultrasound, if the pancreatic tail is visualised, IPAS
usually appears as a solid structure, with identical echogeni-
city to the spleen. Contrast enhanced sonography gives
characteristic enhancement features which may aid differen-
tiation from the surrounding pancreatic tissue and facilitate the
diagnosis of IPAS [4].
Several studies report high success rates using endo-
scopic ultrasound (EUS) with fine needle aspiration for
characterisation of pancreatic tumours, including IPAS, and
its superiority when compared with CT and MRI [5–7].
However in our case, EUS and fine needle biopsy were
inconclusive despite two attempts.3.4. CT
Due to increased availability of CT scanning, improved
resolution and multiphase imaging, there is an increase inresence of a well defined encapsulated intrapancreatic mass
res are identical to that of splenic tissue. Haematoxylin and eosin
e pancreatic and splenic tissue. The splenic tissue is highlighted
CA.
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a contrast enhanced CT depend on the number of phases
used. In our hospital, if a vascular pancreatic pathology is
identified or suspected a triple phase (arterial, pancreatic,
portal/venous) contrast CT is used for further character-
isation. The attenuation of an IPAS, similar to that of the
spleen, is usually higher than the surrounding pancreatic
tissue on all phases, allowing possible identification [8].3.5. MR
Several MR techniques have been used to demonstrate
IPAS as it demonstrates similar MRI enhancement as the
spleen. The use of super paramagnetic iron oxide (SPIO)
enhanced MRI may enable better differentiation between
splenic and pancreatic tissue [7,9]. Another MR modality
used to demonstrate IPAS is diffusion weighted images
(DWI). DWI demonstrates significant differences between
pancreatic and splenic tissue, and has been used to
successfully diagnose IPAS and differentiate it from a
solid pancreatic tumour [9].
3.6. Nuclear medicine
Scintigraphy has been used to diagnose pancreatic
tumours. Technetium-99m heat damaged red blood cell
(HDRB) scintigraphy is reported as being highly specific
for splenic tissue (Ota et al. 1997). Somatostatin receptor
scintigraphy has a high sensitivity for gastro endocrinal
tumours (70–95%) and may help to identify pancreatic
endocrine tumours [10].4. Learning point
In the last five years over forty case reports of
intrapancreatic spleens have been published (PUBMED).
In almost all cases, the clinical history was not typical of a
pancreatic malignancy and IPAS was an incidentalfinding. Less than 15% of case reports had a definitive
diagnosis with imaging, avoiding the need for surgical
resection.
The consequences of missing a potential pancreatic
malignancy are grave, however the risk to the patient of
pancreatic surgery and its sequelae is also considerable.
IPAS should be considered as a diagnosis for tail of the
pancreas tumours and multimodal imaging should be used
before surgical resection of a benign mass.References
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